-
MOASC’s “Researcher of the Month,” highlights the great cancer research happening in Southern California. Sandip Patel, M.D., Medical Oncologist and Associate Professor of Medicine at UCSD. Dr. Patel is Director of Clinical Trials, Deputy Director San Diego Center for Precision Immunotherapy conducts ongoing cancer research in experimental therapeutics. For more information on these trials, email CancerCTO@health.ucsd.edu. Watch his interview: https://lnkd.in/gZjzGzcP
|
|
-
TOMORROW! June 29th MOASC’s Lung Cancer Webinar Series presents Immunotherapy in the Metastatic Settings in Non-Small Cell Lung Cancer. 6:00pm PDT
|
|
-
MOASC is pleased to join Rockpointe in presenting “Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas.” Available until August 2022, this is an on-demand, free CME/CE-certified, webcourse available to MOASC members and to anyone who would like to participate. July 1, 2022.
|
|
-
The Virtual Case-Based Roundtable Meetings are a collaborative, small-group meeting designed around case-based clinical profiles and peer-dialogue led by an expert physician. These sessions offer practicing oncologists the perfect opportunity to sharpen their skills and expertise in treatment strategies. Attendees are paid $500 of compensation by Healthcare Research Analytics® for their attendance, participation & completion of the post-event HRA survey.
|
|
-
An On-Demand webcourse to the breast cancer program MOASC held in April is now available online. Accredited for: ABIM MOC/CME
|
|
-
MOASC’s Spotlight On Clinical Oncology, Saturday, August 27, 2022,Hyatt Huntington Beach, 1:00pm to 7:00pm-PDT. This Activity is approved for AMA PRA Category 1 Credits™
|
|
-
ANCO presents ASCO22 Highlights on August 27th at the InterContinental San Francisco.
|
|
-
Policy and Practice: A CMS Update CA/NV IMPAC updated
|
|
-
New Model to Improve Cancer Care for Medicare Patients, announced by Biden Administration.
|
|
-
The Hill has shared a Comparison of OCM to EOM by Select Model Features
|
|
- COA has commented on Enhanced Oncology Model
|
|
- Bobbi Buell writes about Drug Makers having to Pay for Drug Waste in 2023.
|
|
- CA/NV Noridian IMPAC Meeting
|
|
-
Improper Use of Modifier GY and Bundled Services. Noridian has seen a large volume of status (B) bundled CPT codes billed with the addition of modifier GY. The modifier is being incorrectly used to circumvent the financial liability of the provider to the beneficiary.
|
|
-
2023 ICD-10-CM Diagnosis Codes.
|
|
- July 2022 Quarterly Average Sales Price [ASP]
|
|
-
More than 18 million Americans have now survived cancer per study conducted by the American Cancer Society and the National Cancer Institute.
|
|
- ASCO launches campaign urging Congress to Pass Prior Authorization Reform.
|
|
-
TODAY! June 28 at 4:00pm PDT or 7:00pm PDT. LIVE broadcast highlighting the outcomes of the PROVENT trial for pre-exposure prophylaxis of COVID-19 and recommended approaches to preventing COVID-19 in individuals who have moderate to severe immune compromise.
|
|
-
Join Incyte Corporation for a live webinar about myeloproliferative neoplasms (MPN). Choose from three opportunities:
|
|
-
6th Annual School of Nursing Oncology™ Conference, July 29-30, 2022, Marriott Marquis San Diego Marina Hotel, San Diego, CA. MOASC members discounted registration.
|
|
-
On May 4, 2022, the U.S. Food and Drug Administration (FDA) approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) a HER2-directed antibody drug conjugate, being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.
|
|
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.
|
|
|
|
|
|
|
